An analyser for identifying or verifying a liquid drug for delivery to a patient to reduce risk of adverse drug events, the liquid drug comprising a drug in a base liquid, the liquid drug having a liquid drug spectrum and the base liquid having a base liquid spectrum comprising at least one spectral characteristic feature between about 1300nm and about 2000nm, the analyser comprising: an electromagnetic radiation source for emitting electromagnetic radiation at the liquid drug, the electromagnetic radiation comprising a plurality of different wavelengths spread across about 1300nm to about 2000nm, wherein at least one of the wavelengths is at or in the vicinity of or within a region spanning a wavelength of a spectral characteristic feature of the base liquid spectrum, a liquid drug detector that detects affected electromagnetic radiation resulting from the emitted electromagnetic radiation affected by the liquid drug and that provides output representing spectral information of the liquid drug spectrum at the wavelengths, and a processor configured to identify or verify the liquid drug from the detector output by: querying a database of reference liquid drugs and corresponding spectral information of the reference liquid drugs at the wavelengths, each reference liquid drug comprising a reference drug in a base liquid, each reference liquid drug having a reference liquid drug spectrum and the base liquid having a base liquid spectrum comprising the at least one spectral characteristic feature between about 1300nm and about 2000nm, there being sufficient spectral differences between the reference liquid drug spectrums at the at least one spectral characteristic feature to provide discrimination between reference drugs, identifying or verifying the liquid drug using: a) the detector output representing the spectral information of the liquid drug, and b) the spectral information of the reference liquid drugs, wherein the discrimination between the reference drugs assists with the identifying or verifying the liquid drug. an electromagnetic radiation source for emitting electromagnetic radiation at the liquid drug, the electromagnetic radiation comprising a plurality of different wavelengths spread across about 1300nm to about 2000nm, wherein at least one of the wavelengths is at or in the vicinity of or within a region spanning a wavelength of a spectral characteristic feature of the base liquid spectrum, a liquid drug detector that detects affected electromagnetic radiation resulting from the emitted electromagnetic radiation affected by the liquid drug and that provides output representing spectral information of the liquid drug spectrum at the wavelengths, and a processor configured to identify or verify the liquid drug from the detector output by: querying a database of reference liquid drugs and corresponding spectral information of the reference liquid drugs at the wavelengths, each reference liquid drug comprising a reference drug in a base liquid, each reference liquid drug having a reference liquid drug spectrum and the base liquid having a base liquid spectrum comprising the at least one spectral characteristic feature between about 1300nm and about 2000nm, there being sufficient spectral differences between the reference liquid drug spectrums at the at least one spectral characteristic feature to provide discrimination between reference drugs, identifying or verifying the liquid drug using: a) the detector output representing the spectral information of the liquid drug, and b) the spectral information of the reference liquid drugs, wherein the discrimination between the reference drugs assists with the identifying or verifying the liquid drug. querying a database of reference liquid drugs and corresponding spectral information of the reference liquid drugs at the wavelengths, each reference liquid drug comprising a reference drug in a base liquid, each reference liquid drug having a reference liquid drug spectrum and the base liquid having a base liquid spectrum comprising the at least one spectral characteristic feature between about 1300nm and about 2000nm, there being sufficient spectral differences between the reference liquid drug spectrums at the at least one spectral characteristic feature to provide discrimination between reference drugs, identifying or verifying the liquid drug using: a) the detector output representing the spectral information of the liquid drug, and b) the spectral information of the reference liquid drugs, wherein the discrimination between the reference drugs assists with the identifying or verifying the liquid drug.